News Briefing channel feed

JAK in­hibitor PDU­FA dates ex­tend­ed again as safe­ty re­view con­tin­ues; Stem­son se­cures $15M to cure hair loss

4 years ago

Eli Lil­ly part­ners with Alzheimer's cen­ter for PhI­II study; New tu­ber­cu­lo­sis con­sor­tium emerges in $218M+ project

4 years ago

Tri­al soft­ware group rais­es $45M to push de­cen­tral­ized stud­ies; $120M SPAC makes its way to Nas­daq

4 years ago

Astel­las signs on pluripo­tent stem cell part­ners at Ex­CellThera; Lit­tle Uni­cy­cive brings home $25M af­ter float­ing a small IPO

4 years ago

WHO is­sues new guide­lines for gene edit­ing; Doud­na-backed Cari­bou launch­es its first al­lo­gene­ic CAR-T tri­al

4 years ago

With TransCode go­ing pub­lic, in­dus­try sur­pass­es $10B IPO mark; Galect­in's in­hibitor shows PhIb suc­cess in can­cer treat­ment

4 years ago

Bridge­Bio adds 3 more in­sti­tu­tions to its ros­ter of col­lab­o­ra­tors; Ex­sci­en­tia lands Gates Foun­da­tion mon­ey for Covid-19 pill 

4 years ago

Ar­row­head touts Phase Ib RNAi da­ta for ccR­CC; PureTech lines up PD-1 from BeiGene for up­com­ing com­bo study

4 years ago

Chemo­Cen­tryx gets new PDU­FA date af­ter ma­jor amend­ment; Nim­i­um launch­es with eye on obe­si­ty

4 years ago

Sar­to­rius buys ma­jor­i­ty stake in Ger­man man­u­fac­tur­ing play­er; Cerev­el Ther­a­peu­tics ends the week on a high note, with $350M raise

4 years ago

Kin­tara of­fers peek at mid-stage da­ta in re­lapsed glioblas­toma pa­tients; Jazz wins quick ap­proval for pe­di­atric can­cer drug

4 years ago

3 gene ther­a­py com­pa­nies se­cure VC mon­ey; No­valis clos­es near­ly $30 mil­lion fund

4 years ago

Io­vance's TIL ther­a­py makes ear­ly head­way in lung can­cer; An­tios and Ar­bu­tus join hands on HBV com­bo treat­ment

4 years ago

Sanofi kicks off PhII test for RIPK1 in­hibitor, trig­ger­ing De­nali mile­stone; Ital­ian biotech flops key end­point in mus­cu­lar dy­s­tro­phy study

4 years ago

ACIP unan­i­mous­ly rec­om­mends Deng­vax­ia use, with same caveats as FDA la­bel; Chi­nese 3D print­ing com­pa­ny with rheuma­toid arthri­tis drug com­pletes Se­ries B fi­nanc­ing

4 years ago

Ab­b­Vie snaps up a bis­pe­cif­ic for mul­ti­ple myelo­ma in TeneoOne buy­out; Ver­tex launch­es $1.5B share buy­back pro­gram

4 years ago

Hutchmed/As­traZeneca lung can­cer drug gets OK in Chi­na; Enan­ta re­ports PhIb da­ta for their oral he­pati­tis B pro­gram

4 years ago

Roche's Alzheimer's drug spurred bio­mark­er changes but no cog­ni­tive im­pact — pa­per; vTv out-li­cens­es for­mer lead pro­gram

4 years ago

As Hutchmed awaits FDA ap­proval for su­r­u­fa­tinib, drug gets the go-ahead in Chi­na; SCO­TUS knocks back last Amarin patent bid

4 years ago

Jim Green­wood opens new pol­i­cy shop, with an eye on drug price con­trols; Mod­er­na, CRISPR, Mus­tang re­ceive tax breaks in Mass­a­chu­setts

4 years ago

Don’t hold your breath wait­ing for FDA nom­i­nee; A pri­or­i­ty re­view for an­oth­er Bris­tol My­ers part­ner

4 years ago

No­vo Nordisk to re­search oral obe­si­ty treat­ment; Dana-Far­ber taps in­to Har­bour Bio­Med's mice plat­form in mul­ti­year deal

4 years ago

Is­rael's VBL Ther­a­peu­tics hit with CMC de­lays in ovar­i­an can­cer study; No­vo Hold­ings buys out di­ag­nos­tics play­er BBI

4 years ago

FDA push­es back As­cendis' PDU­FA for long-act­ing hor­mone ther­a­py; De­bio­pharm takes home a win in mid-stage test for ADC

4 years ago
First page Previous page 29303132333435 Next page Last page
A service from the Financial Times